share_log

Tonix Pharmaceuticals Has Enrolled The First Participant In Phase 2 'POWER' Study Of TNX-1900 (Intranasal Potentiated Oxytocin) For Pediatric Obesity At The Massachusetts General Hospital

Benzinga ·  Jul 10, 2023 07:06
Tonix Pharmaceuticals Has Enrolled The First Participant In Phase 2 'POWER' Study Of TNX-1900 (Intranasal Potentiated Oxytocin) For Pediatric Obesity At The Massachusetts General Hospital
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment